Article Text

Download PDFPDF
Diabetes: can we stop the time bomb?
  1. M Fisher
  1. Correspondence to:
    Dr Miles Fisher, Glasgow Royal Infirmary, Glasgow G31 2ER, UK;
    miles.fisher{at}northglasgow.scot.nhs.uk

Abstract

Type 2 diabetes is increasing in prevalence and it is estimated that three million individuals in the UK will have the disease by 2010. People with diabetes have a high risk of cardiovascular disease—coronary heart disease is more prevalent, more extensive, and more diffuse. For all cardiovascular syndromes, the mortality is virtually doubled in patients with diabetes. Large clinical trials have provided clear evidence of the reduction in cardiovascular risk that can be achieved by treating hyperglycaemia as well as traditional risk factors, such as hypertension and hyperlipidaemia. The challenge now is for all health care professionals to implement the treatment guidelines.

  • diabetes
  • cardiovascular disease
  • ACE, angiotensin converting enzyme
  • ALLHAT, Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial
  • CAPRIE, Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events
  • CARE, Cholesterol and Recurrent Events
  • DAIS, Diabetes Atherosclerosis Intervention Study
  • HOPE, Heart Outcomes Prevention Evaluation
  • LIPID, Long term Intervention with Pravastatin in Ischaemic Disease
  • LIPS, Lescol Intervention Prevention Study
  • UKPDS, UK Prospective Diabetes Study
  • VA-HIT, Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial
  • 4S, Scandinavian Simvastatin Survival Study

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.